Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8Neoplasms 4Pain, Postoperative 2Hemangioma, Capillary 2Carcinoma, Hepatocellular 2Anxiety Disorders 2Weight Loss 1Vomiting 1Urinary Incontinence, Stress 1Urinary Incontinence 1Urinary Bladder Neoplasms 1Shoulder Pain 1SCLC, Limited Stage 1Respiratory Aspiration 1Psychomotor Agitation 1Prostatic Neoplasms 1Premature Birth 1Polycystic Ovary Syndrome 1Pediatric Obesity 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cysts 1Obesity 1Neuromuscular Diseases 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Myofibroma 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Multiple Myeloma 1

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myasthenia Gravis × Population Groups × Clear all
NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡